Skip To Main Content

Áreas terapeúticas

Descubra la más reciente actualización sobre la evidencia científica y los datos basados en la vida real que se han recopilado en el campo de la epidemiología. Esta información incluye detalles sobre la carga que estas enfermedades imponen a las personas y a la sociedad en general, así como los métodos de control que se están implementando para hacer frente a estas situaciones.

También se aborda el impacto económico que tienen enfermedades como asma grave, cardiovascular, dermatitis atópica, diabetes o enfermedades raras, etc., en la vida de nuestra población. Estos elementos son fundamentales para comprender la magnitud del problema y para desarrollar estrategias efectivas que ayuden a mejorar la salud pública.

Ordenar por

Patología

Limpiar filtro
  • Filtros
How to inject Toujeo (insulin glargine 300U/mL)

How to inject Toujeo (insulin glargine 300U/mL)

Educate your patients on correct injection technique for Toujeo

Switching to Toujeo® (insulin glargine 300 units/mL) from other regimens

Switching to Toujeo® (insulin glargine 300 units/mL) from other regimens

A clinical guide for healthcare professionals on switching patients to Toujeo® (insulin glargine 300 units/mL) from other insulin regimens.

Toujeo: Insulin Naive start Guide

Toujeo: Insulin Naive start Guide

Insulin is one of the most effective glucose-lowering agents for type 2 diabetes and can be titrated to suit an individual patient’s requirements.

Seznam PCSK9i center

Seznam PCSK9i center

V tomto článku se dozvíte, kde najít seznam všech PCSK9i center.

DUPIXENT® - WISSEN kompakt

DUPIXENT® - WISSEN kompakt

Protecting Pilgrims: Meningococcal Disease Risk Factors During Mass Gatherings

Protecting Pilgrims: Meningococcal Disease Risk Factors During Mass Gatherings

Comprehensive analysis of meningococcal disease risk factors during mass religious gatherings, with focus on the Hajj pilgrimage. Details environmental challenges, demographic vulnerabilities, and transmission dynamics among pilgrims, local residents, and healthcare workers in Mecca, with emphasis on crowded conditions and N. meningitidis carriage rates.

Meningococcal Vaccination Impact: Hajj Pilgrimage Case Studies and Global Benefits

Meningococcal Vaccination Impact: Hajj Pilgrimage Case Studies and Global Benefits

Comprehensive analysis of meningococcal vaccine effectiveness during Hajj pilgrimages, featuring case studies from Singapore and Saudi Arabia. Highlights significant reduction in IMD cases post-vaccination and explores the broader benefits of meningococcal conjugate vaccines, including herd immunity and reduced global transmission.

Age and Serogroup Patterns: IMD in South Africa

Age and Serogroup Patterns: IMD in South Africa

Comprehensive analysis of Invasive Meningococcal Disease (IMD) patterns in South Africa, featuring GERMS-SA surveillance data from 2018-2024. Highlights age-specific incidence rates, with detailed focus on infant vulnerability (1.6 per 100,000) and adolescent/young adult peaks. Includes serogroup distribution trends across the country.

Age-Related Risk Factors for IMD: From Infants to Elderly

Age-Related Risk Factors for IMD: From Infants to Elderly

Comprehensive overview of age-specific risk factors for Invasive Meningococcal Disease (IMD), detailing vulnerability patterns across different life stages. Features specific risks for infants, adolescents, and elderly populations, including the impact of maternal antibody decline, nasopharyngeal colonization, and immunosenescence in older adults.

Clinical Recognition of IMD: Symptoms, Signs, and Presentations

Clinical Recognition of IMD: Symptoms, Signs, and Presentations

Comprehensive guide to clinical presentations of Invasive Meningococcal Disease (IMD), detailing key symptoms of meningitis, meningococcemia, and septic shock. Features diagnostic criteria including fever, headache, photophobia, petechial rash, and less common manifestations such as pneumonia and arthritis. Essential reference for healthcare providers and medical professionals.

Understanding N. meningitidis: Biology, Serogroups, and Carriage

Understanding N. meningitidis: Biology, Serogroups, and Carriage

Comprehensive overview of Neisseria meningitidis, detailing bacterial characteristics, serogroups, and age-specific carriage patterns. Features evidence from European meta-analysis of 89 studies, highlighting carriage rates from infancy through adulthood and the relationship between carriage and invasive disease.

IMD Consequences: Mortality, Sequelae, and Long-term Impact

IMD Consequences: Mortality, Sequelae, and Long-term Impact

Comprehensive analysis of Invasive Meningococcal Disease (IMD) outcomes, featuring detailed mortality rates by serogroup and age group, with focus on the 20% survivor sequelae rate. Includes comparative analysis with other vaccine-preventable diseases (VPDs) and highlights the critical 24-hour window for treatment intervention.

Material diseñado por o para Sanofi Aventis de Colombia S.A., con fines educativos y dirigido a profesionales de la salud y personal administrativo del sector salud. Es estrictamente prohibido compartir este material con terceros.

Mayor información a disposición en el Departamento Médico:

En Colombia:

Sanofi-Aventis de Colombia S.A. Transversal 23 N° 97-73 - Edificio City Business. Piso 8. Bogotá D.C. Teléfono: 621 4400 - Fax: 744 4237

infomedica.colombia@sanofi.com

En Bolivia, Centro América y Caribe:

Sanofi-Aventis de Panamá S.A. Torre Evolution, piso 26, Calle 50 y Av. Aquilino de la Guardia Obarrio- Cuidad de Panamá, República de Panamá Telf.: (507) 382-9500. infomed.pac@sanofi.com

Sitio web: http://www.sanofi.com.pa/l/pa/sp/index.jsp

 

MAT-CO-2400825 V1.0 03/2024